Recently, it is reported that ATRA could inhibit the expression of MYB and dramatically lower the level of the oncogenic fusion protein, suggesting a potential treatment agent for R/M ACC.20, 21. The gene discussed is MYB; the disease is adrenal cortex carcinoma.